Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

Inclusion Criteria:

- Diagnosis of COPD

- Age: >= 40 years

- Current or ex-smoker with a >= 10 pack-year smoking history

- Use of Combivent® MDI for >= 1 month prior to Visit 1 Spirometric criteria (determined
at study visits):

- Post-bronchodilator FEV1 <= 70% (Visit 1)

- Pre-bronchodilator FEV1 <= 65% of predicted and FEV1/FVC <= 70% (Visit 2)

Exclusion Criteria:

- Clinical history of asthma

- History of thoracotomy with pulmonary resection

- History of CF, alpha 1 antitrypsin deficiency or interstitial lung disease

- Daytime use of oxygen therapy for > 1 hour per day or if unable to abstain from using
oxygen during PFTs

- Any respiratory tract infection or COPD exacerbation in 6 weeks prior to Visit 1

- Recent history 6 months or less of MI

- Unstable or life-threatening cardiac arrhythmias

- Hospitalization for CHF during past year

- Malignancy for which patient is receiving chemo or radiation therapy

- Pregnant or nursing women

- Known hypersensitivity to ipratropium or carrier substances, including related food
products such as soybean, peanuts, or lactose

- Use of SPIRIVA® 3 months prior to Visit 1

- Symptomatic of prostatic hypertrophy or bladder neck obstruction

- Known narrow- angle glaucoma

- Participating in a pulmonary rehab program within 4 weeks of Visit 1